Can osimertinib/osimertinib treat cancer metastasis?

Osimertinib/Osimertinib (Osimertinib) is commonly used to treat advanced non-small cell lung cancer (NSCLC), especially patients with EGFR (epidermal growth factor receptor) mutation-positive patients. For cancer metastasis in patients with lung cancer, Osimertinib may be considered as a treatment option under certain circumstances. Cancer metastasis of lung cancer usually refers to the spread of tumor cells from the primary tumor to other parts, such as brain, bone, liver, adrenal gland, etc. EGFRMutation is a common molecular marker of lung cancer and is associated with the growth, spread and drug resistance of lung cancer. Osimertinib/OsimertinibAs a targeted therapy drug, it can effectively inhibit the growth and spread of lung cancer cells by inhibiting EGFRkinase activity. Therefore, for lung cancer patients with metastasis, especially those with positive EGFR mutations, Osimertinib may be considered by doctors as part of the treatment plan. However, the selection of treatment options still needs to be comprehensively considered and individualized based on factors such as the patient's specific situation, disease stage, and treatment goals.